Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
mi
from
Milwaukee, WI
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Palm Beach Cancer Institute - West Palm Beach
mi
from
West Palm Beach, FL
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Palm Beach Cancer Institute - West Palm Beach
mi
from
West Palm Beach, FL
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Cost Utility Analysis in Recurrent Ovarian Cancer
Quality of Life and Cost Utility Analysis in the Treatment of Recurrent, Platinum-Resistant Ovarian Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cost Utility Analysis in Recurrent Ovarian Cancer
Quality of Life and Cost Utility Analysis in the Treatment of Recurrent, Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Univ. of New Mexico cancer research and treatment center
mi
from
Albuquerque, NM
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Univ. of New Mexico cancer research and treatment center
mi
from
Albuquerque, NM
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Bellevue Hospital Center
mi
from
New York, NY
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Bellevue Hospital Center
mi
from
New York, NY
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
St Joseph's Hospital Comprehensive Research Institute
mi
from
Tampa, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
St Joseph's Hospital Comprehensive Research Institute
mi
from
Tampa, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Arizona Hematology & Oncology Associates
mi
from
Phoenix, AZ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Arizona Hematology & Oncology Associates
mi
from
Phoenix, AZ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Arizona Oncology Associates
mi
from
Tucson, AZ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Arizona Oncology Associates
mi
from
Tucson, AZ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
California Cancer Care
mi
from
Greenbrae, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
California Cancer Care
mi
from
Greenbrae, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Catholic Health Initiatives
mi
from
Colorado Springs, CO
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Catholic Health Initiatives
mi
from
Colorado Springs, CO
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Denver Health and Hospital Authority
mi
from
Denver, CO
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Denver Health and Hospital Authority
mi
from
Denver, CO
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Washington Hospital Center
mi
from
Washington,
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Washington Hospital Center
mi
from
Washington,
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
University Cancer Institute
mi
from
Boyton Beach, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
University Cancer Institute
mi
from
Boyton Beach, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Gainesville Hematology Oncology Associates
mi
from
Gainesville, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Gainesville Hematology Oncology Associates
mi
from
Gainesville, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Baptist Cancer Center
mi
from
Jacksonville, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Baptist Cancer Center
mi
from
Jacksonville, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Jupiter Medical Center
mi
from
Jupiter, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Jupiter Medical Center
mi
from
Jupiter, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Hematology-Oncolgy Associates of NNJ-PA
mi
from
Denville, NJ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Hematology-Oncolgy Associates of NNJ-PA
mi
from
Denville, NJ
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Florida Hospital
mi
from
Orlando, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Florida Hospital
mi
from
Orlando, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Sarasota Memorial Health Care System
mi
from
Sarasota, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Sarasota Memorial Health Care System
mi
from
Sarasota, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Gulfcoast Oncology Associates
mi
from
St. Petersburg, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Gulfcoast Oncology Associates
mi
from
St. Petersburg, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Oncology-Hematology Associates of W. Broward P.A.
mi
from
Tamarac, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Oncology-Hematology Associates of W. Broward P.A.
mi
from
Tamarac, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Palm Beach Cancer Institute - West Palm Beach
mi
from
West Palm Beach, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Palm Beach Cancer Institute - West Palm Beach
mi
from
West Palm Beach, FL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Med College of Georgia
mi
from
Augusta, GA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Med College of Georgia
mi
from
Augusta, GA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Memorial Health University Medical Center
mi
from
Savannah, GA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Memorial Health University Medical Center
mi
from
Savannah, GA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Kaiser Foundation Hospital-San Diego
mi
from
San Diego, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Kaiser Foundation Hospital-San Diego
mi
from
San Diego, CA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Kapi'olani Medical Center for Women and Children
mi
from
Honolulu, HI
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Kapi'olani Medical Center for Women and Children
mi
from
Honolulu, HI
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Ingalls Cancer Research Center
mi
from
Harvey, IL
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Ingalls Cancer Research Center
mi
from
Harvey, IL